Amir Horowitz: Treatment strategies and management of BCG-unresponsive NMIBC

Amir Horowitz shared on X:

“Honored to play small role in shaping guidelines for treatment strategies and management of BCG-unresponsive NMIBC under the brilliant efforts of Ashish M. Kamat and IBCG.”

Source: Amir Horowitz/X

Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.

Authors: Roger Li, Patrick J. Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Peter C. Black, Maurizio Brausi, Kelly K. Bree, Mario I. Fernández, Charles C. Guo, Amir Horowitz, Donald L. Lamm, Seth P. Lerner, Yair Lotan, Paramananthan Mariappan, David McConkey, Laura S. Mertens, Carmen Mir, Jeffrey S. Ross, Michael O’Donnell, and Ashish M. Kamat.

Amir Horowitz, PhD is an Assistant Professor of Oncological Sciences and a member of the Precision Immunology Institute and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. He pioneered the first studies of human NK cells by mass cytometry (CyTOF^TM).